Results 201 to 210 of about 67,306 (265)

From anthelmintic to neuro‐oncology: A systematic review of mebendazole repurposing for brain tumour therapy

open access: yesBritish Journal of Clinical Pharmacology, EarlyView.
Abstract Aim Mebendazole (MBZ), a benzimidazole anthelmintic with established clinical use, has emerged as a repurposing candidate for primary brain tumours due to its multimodal anticancer actions and central nervous system penetrance. This systematic review synthesizes preclinical and clinical evidence evaluating MBZ's efficacy, mechanisms of action ...
Ciara B. Blum   +5 more
wiley   +1 more source

PrEP at the site of action in cisgender and transgender women: A pharmacology study of blood and rectal CD4+ lymphocytes

open access: yesBritish Journal of Clinical Pharmacology, EarlyView.
Background Female sex hormones used in feminizing hormone therapy (FHT) may influence activation and persistence of HIV pre‐exposure prophylaxis (PrEP) medications. The clinical relevance of this interaction remains unclear, particularly for transgender and cisgender women (TGW and CGW).
Elizabeth Hastie   +10 more
wiley   +1 more source

Multimodal brain MRI and clinical data in olfactory groove meningioma: a prospective data report. [PDF]

open access: yesFront Radiol
Filimonova E   +7 more
europepmc   +1 more source

Oseltamivir drug‐disease modelling in infants with influenza virus infection

open access: yesBritish Journal of Clinical Pharmacology, EarlyView.
Abstract Aims Oseltamivir is a commonly used neuraminidase inhibitor for treatment of influenza infection, but little data exist regarding concentration‐response relationships. Methods Pharmacokinetic (PK) and viral dynamic data from an earlier NIAID Collaborative Antiviral Study Group trial in paediatric patients with influenza from 0–23 months of age
Kun Wang   +4 more
wiley   +1 more source

A Multi-Site Study of Brief Cognitive-Behavioural Therapy for Eating Disorders for Individuals With BMI ≥ 30. [PDF]

open access: yesEur Eat Disord Rev
Dunford A   +16 more
europepmc   +1 more source

Home - About - Disclaimer - Privacy